Table 3 The relationship between m6A enzymes and cancer treatment
Classification | Cancer Type | M6A Related Enzymes | Biological Behavior Changes | References |
|---|---|---|---|---|
Chemotherapy | Pancreatic cancer | METTL3 | Decrease sensitivity to gemcitabine, 5-FU and cisplatin | [39] |
Non-small cell lung cancer | YTHDF1 | Promote chemosensitivity to cisplatin | [155] | |
Colorectal cancer | YTHDF1 | Promote cisplatin resistance through reprogram GLS1-glutamine metabolism | [156] | |
Leukemia | FTO | Promote resistance to tyrosine kinase inhibitor (TKI) | [157] | |
Ovarian cancer | FTO; ALKBH5 | Promote the sensitivity to PARP inhibitor resistance | [158] | |
Pancreatic ductal adenocarcinoma | ALKBH5 | Promote chemosensitize to gemcitabine | [49] | |
Immunotherapy | Colorectal cancer and melanoma | METTL3; METTL14; YTHDF2 | Decrease the response of pMMR-MSI to PD-1 treatment | [159] |
Tumor | FTO | Resistance to toxic T cells | [161] | |
Radiotherapy | Pancreatic cancer | METTL3 | Decrease the sensitivity to irradiation | [39] |
Lung adenocarcinoma | IGF2BP2/3 | Decrease the harmful effects of radiation on lung adenocarcinoma | [106] | |
Cervical squamous cell carcinoma | FTO | Enhance chemo-radiotherapy resistance | [162] | |
GBMs | METTL3 | Promote resistance of cancer cells to γ-irradiation | [163] |